Through academic collaborations and its own research, Cleara currently has the following compounds against senescence-driven pathologies in its research pipeline:

Our platform for development of subtype-specific antisenescence compounds

Senescent cells are drivers of numerous chronic pathologies. They are thought to do so through chronic secretion of (pro-inflammatory) factors to their environment. Cleara’s scientists identified that there are different kinds of senescence. This argues for individual compounds for their selective elimination.